Evidence map›Paper›PMID 34141048›Full record

ArticleThe World Allergy Organization journal2021

How are patients with chronic urticaria interested in using information and communication technologies to guide their healthcare? A UCARE study.

Ivan Cherrez-Ojeda, Emanuel Vanegas, Annia Cherrez, Miguel Felix, Karsten Weller, Markus Magerl, Rasmus Robin Maurer, Valeria L Mata, Alicja Kasperska-Zajac, Agnieszka Sikora and 27 more

Open access · goldAbstract read
In one paragraph

Article in The World Allergy Organization journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. CRUSEClinical and translational allergy · 2024
    Article
  5. A Patient Charter for Chronic Urticaria.Advances in therapy · 2024
    Article
  6. Reinventing the wheal: A review of online misinformation and conspiracy theories in urticaria.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2023
    Review
  7. Urticaria.Nature reviews. Disease primers · 2022
    Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors at 20 institutions in 16 countries.

Ivan Cherrez-OjedaUniversidad Espíritu Santo, Samborondón, Ecuador.
Emanuel VanegasUniversidad Espíritu Santo, Samborondón, Ecuador.
Annia CherrezRespiralab, Respiralab Research Group, Guayaquil, Ecuador.
Miguel FelixUniversidad Espíritu Santo, Samborondón, Ecuador.
Karsten WellerDermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Germany.
Markus MagerlDermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Germany.
Rasmus Robin MaurerDermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Germany.
Valeria L MataUniversidad Espíritu Santo, Samborondón, Ecuador.
Alicja Kasperska-ZajacEuropean Center for Diagnosis and Treatment of Urticaria, Medical University of Silesia, Katowice, Poland.
Agnieszka SikoraEuropean Center for Diagnosis and Treatment of Urticaria, Medical University of Silesia, Katowice, Poland.
Daria FominaCity Center of Allergy and Immunology, Clinical City Hospital #52, Moscow, Russia.
Elena KovalkovaCity Center of Allergy and Immunology, Clinical City Hospital #52, Moscow, Russia.
Kiran GodseDepartment of Dermatology, D Y, Patil University School of Medicine and Hospital, Mumbai, India.
Nimmagadda Dheeraj RaoDepartment of Dermatology, D Y, Patil University School of Medicine and Hospital, Mumbai, India.
Maryam KhoshkhuiAllergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Sahar RastgooDepartment of Allergy and Immunology, Mashhad University of Medical Sciences, Mashhad, Iran.
Roberta Fj CriadoDepartment of Dermatology, Faculdade de Medicina do ABC, São Paulo, Brazil.
Mohamed AbuzakoukAllergy and Immunology Department, Cleveland Clinic Abu Dhabi, United Arab Emirates.
Deepa GrandonAllergy and Immunology Department, Cleveland Clinic Abu Dhabi, United Arab Emirates.
Martijn B A Van DoornDepartment of Dermatology, Erasmus MC, Rotterdam, the Netherlands.
Solange Oliveira Rodrigues ValleDepartment of Internal Medicine, Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil.
Eduardo Magalhães De Souza LimaFaculty of Science and Health of Juiz de Fora - SUPREMA, Minas Gerais, Brazil.
Simon Francis ThomsenDepartment of Dermatology, Bispebjerg Hospital, University of Copenhagen, Biomedical Sciences, Copenhagen, Denmark.
German D RamónInstituto de Alergia e Inmunología del Sur, Bahía Blanca, Prov. De Buenos Aires, Argentina.
Edgar E Matos BenavidesCentro de Referencia de Alergia, Asma e Inmunología - Instituto Nacional del Niño, Lima, Perú.
Andrea BauerDepartment of Dermatology, University Allergy Center, University Hospital Carl Gustav Carus, Technical University, Dresden, Germany.
Ana M Giménez-ArnauDepartment of Dermatology, Hospital del Mar, IMIM, Universitat Autònoma, Barcelona, Spain.
Emek KocatürkDepartment of Dermatology, Koç University School of Medicine, Istanbul, Turkey.
Carole GuilletDepartment of Dermatology, University Hospital Zurich, Switzerland.
Jose Ignacio LarcoAllergy Department, Clinica San Felipe, Lima, Peru.
Zuo-Tao ZhaoDepartment of Dermatology and Venereology, Peking University First Hospital, Beijing, China.
Michael MakrisAllergy Unit, 2nd Department of Dermatology and Venereology, National and Kapodistrian, University of Athens, "Attikon" University Hospital, Greece.
Carla RitchieAllergy Division, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Paraskevi XepapadakiAllergy Department, 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Greece.
Luis Felipe EnsinaFederal University of São Paulo. São Paulo, Brazil.
Sofia CherrezRespiralab, Respiralab Research Group, Guayaquil, Ecuador.
Marcus MaurerDermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Germany.
Charité - Universitätsmedizin Berlin · DEUniversidad de Especialidades Espíritu Santo · ECCity Clinical Hospital · RUD.Y. Patil University · INMashhad University of Medical Sciences · IRMedical University of Silesia · PLNational and Kapodistrian University of Athens · GRCentro Peruano de Estudios Sociales · PEErasmus MC · NLFaculdade de Medicina do ABC · BRHospital Italiano de Buenos Aires · ARHospital Universitário Clementino Fraga Filho · BRInstituto de Física del Sur · ARInstituto Nacional de Salud del Niño · PEKlinik für Psychosomatik · DEKoç University · TRPeking University First Hospital · CNUniversidade Federal de São Paulo · BRUniversitat Autònoma de Barcelona · ESUniversity Hospital Carl Gustav Carus · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with chronic urticaria (CU) are increasingly using information and communication technologies (ICTs) to manage their health. What CU patients expect from ICTs and which ICTs they prefer remains unknown. We assessed why CU patients use ICTs, which ones they prefer, and what drives their expectations and choices.

methodsIn this cross-sectional study, 1841 patients across 17 countries were recruited at UCAREs (Urticaria Centers of Reference and Excellence). Patients with CU who were >12 years old completed a 23-item questionnaire.

resultsMost patients were interested in receiving disease information (87.3%), asking physicians about CU (84.1%), and communicating with other patients through ICTs (65.6%). For receiving disease information, patients preferred one-to-one and one-to-many ICTs, especially web browsers. One-to-one ICTs were also the ICTs of choice for asking physicians about urticaria and for communicating with other patients, and e-mail and WhatsApp were the preferred ICTs, respectively. Many-to-many ICTs such as Facebook, Instagram, LinkedIn, and Twitter were least preferred for all 3 purposes. Living in rural areas and higher education were linked to higher odds of being interested in receiving disease information, asking physicians, and communicating with patients through ICTs.

conclusionsMost patients and especially patients with higher education who live in rural areas are interested in using ICTs for their healthcare, but prefer different ICTs for different purposes, ie, web browsers for obtaining information, e-mail for asking physicians, and WhatsApp for communicating with other patients. Our findings may help to improve ICTs for CU.

Indexed as

Chronic urticariae-mailInformation and communication technologiesInternetWhatsApp

Identifiers

PMID34141048
PMCPMC8190491
OpenAlexW3169494026

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.